Pacira Biosciences, Inc. (PCRX)
36.33
-0.07
(-0.19%)
USD |
NASDAQ |
Oct 15, 16:00
36.60
+0.27
(+0.74%)
After-Hours: 04:10
Pacira Biosciences Research and Development Expense (Quarterly) : 30.24M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 30.24M |
| March 31, 2026 | 28.07M |
| December 31, 2025 | 37.45M |
| September 30, 2025 | 25.97M |
| June 30, 2025 | 28.20M |
| March 31, 2025 | 25.34M |
| December 31, 2024 | 23.90M |
| September 30, 2024 | 19.10M |
| June 30, 2024 | 20.34M |
| March 31, 2024 | 18.24M |
| December 31, 2023 | 19.46M |
| September 30, 2023 | 20.83M |
| June 30, 2023 | 18.82M |
| March 31, 2023 | 17.14M |
| December 31, 2022 | 17.50M |
| September 30, 2022 | 19.40M |
| June 30, 2022 | 26.28M |
| March 31, 2022 | 21.60M |
| December 31, 2021 | 15.51M |
| September 30, 2021 | 11.58M |
| June 30, 2021 | 12.57M |
| March 31, 2021 | 15.88M |
| December 31, 2020 | 15.33M |
| September 30, 2020 | 14.65M |
| June 30, 2020 | 13.62M |
| Date | Value |
|---|---|
| March 31, 2020 | 15.82M |
| December 31, 2019 | 19.65M |
| September 30, 2019 | 20.26M |
| June 30, 2019 | 17.83M |
| March 31, 2019 | 14.38M |
| December 31, 2018 | 14.17M |
| September 30, 2018 | 14.90M |
| June 30, 2018 | 12.24M |
| March 31, 2018 | 14.38M |
| December 31, 2017 | 10.03M |
| September 30, 2017 | 11.78M |
| June 30, 2017 | 18.86M |
| March 31, 2017 | 16.63M |
| December 31, 2016 | 17.07M |
| September 30, 2016 | 9.754M |
| June 30, 2016 | 9.362M |
| March 31, 2016 | 9.493M |
| December 31, 2015 | 13.15M |
| September 30, 2015 | 5.893M |
| June 30, 2015 | 3.649M |
| March 31, 2015 | 5.967M |
| December 31, 2014 | 3.886M |
| September 30, 2014 | 4.425M |
| June 30, 2014 | 5.216M |
| March 31, 2014 | 5.204M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Viatris, Inc. | 245.20M |
| Johnson & Johnson | 4.652B |
| Liquidia Corp. | 16.88M |
| Organon & Co. | 90.00M |
| ANI Pharmaceuticals, Inc. | 14.75M |